Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: A randomized, double-blind, placebo-controlled trial

被引:33
|
作者
Boon, R [1 ]
Goodman, JJ [1 ]
Martinez, J [1 ]
Marks, GL [1 ]
Gamble, M [1 ]
Welch, C [1 ]
机构
[1] SmithKline Beecham Consumer Healthcare, Res & Dev, Surrey KT10 0DE, England
关键词
penciclovir; herpes labialis; sunlight; symptoms; attributes;
D O I
10.1016/S0149-2918(00)87979-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The purpose of this study was to further define the therapeutic value of penciclovir cream in the treatment of sunlight-induced herpes labialis by comparing its efficacy and tolerability with those of an inactive control (purified water). Methods: In this randomized, double-blind, placebo-controlled, parallel-group clinical trial, lesions were induced by exposure to sunlight. Treatment was self-initiated within 1 hour of development of the signs or symptoms of a recurrence. Results: Healthy male and female patients (mean age, 38.3 years; range, 18 to 81 years) who had a history of sunlight-induced herpes labialis (mean of 6 recurrences in previous 12 months) applied either penciclovir cream (n = 266) or purified water (n = 275). Penciclovir cream significantly decreased the time to lesion healing (P < 0.001), with a reduction in median time of up to 2 days. The efficacy of penciclovir cream was further supported by a significant reduction in maximum lesion area (P = 0.008), a faster loss of lesion-associated symptoms (P = 0.026), and significant reductions in daily assessments of pain (P less than or equal to 0.040), itching (P less than or equal to 0.032), burning (P less than or equal to 0.028), and tenderness (P less than or equal to 0.026) as moderate or severe. These effects were reinforced by the results of the daily self-assessment of lesion attributes, with significantly fewer severe/extreme assessments of lesion size (P less than or equal to 0.003), noticeability (P less than or equal to 0.003), amount of scab/crust (P less than or equal to 0.003), raised/ swollen area (P less than or equal to 0.040), soreness/tenderness (P less than or equal to 0.043), and overall severity (P less than or equal to 0.001) throughout the study period. Conclusions: Penciclovir cream has demonstrated efficacy for a bread range of clinically important outcomes. Significant effects on lesion area, lesion symptoms, and other lesion attributes extend the clinical efficacy of penciclovir cream beyond lesion healing.
引用
收藏
页码:76 / 90
页数:15
相关论文
共 50 条
  • [41] Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial
    Coffin, Phillip Oliver
    Santos, Glenn-Milo
    Das, Moupali
    Santos, Deirdre M.
    Huffaker, Shannon
    Matheson, Tim
    Gasper, James
    Vittinghoff, Eric
    Colfax, Grant N.
    ADDICTION, 2013, 108 (04) : 751 - 761
  • [42] Gabapentin in the treatment of fibromyalgia - A randomized, double-blind, placebo-controlled, multicenter trial
    Arnold, Lesley M.
    Goldenberg, Don L.
    Stanford, Sharon B.
    Lalonde, Justine K.
    Sandhu, H. S.
    Keck, Paul E., Jr.
    Welge, Jeffrey A.
    Bishop, Fred
    Stanford, Kevin E.
    Hess, Evelyn V.
    Hudson, James I.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (04): : 1336 - 1344
  • [43] Ziprasidone in the acute treatment of mania: A double-blind, placebo-controlled, randomized trial
    Giller, E
    Mandel, FS
    Keck, P
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 229 - 229
  • [44] RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF KETANSERIN IN TREATMENT OF INTERMITTENT CLAUDICATION
    WALDEN, R
    BASS, A
    RABI, I
    ADAR, R
    JOURNAL OF CARDIOVASCULAR SURGERY, 1991, 32 (06): : 737 - 740
  • [45] Randomized, double-blind, placebo-controlled trial of rofecoxib for the acute treatment of migraine
    Tepper, S
    Silberstein, S
    Brandes, J
    Venkatraman, S
    Vrijens, F
    Malbecq, W
    Visser, WH
    Reines, S
    Yuen, E
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 300 - 300
  • [46] Acute migraine treatment with droperidol - A randomized, double-blind, placebo-controlled trial
    Silberstein, SD
    Young, WB
    Mendizabal, JE
    Rothrock, JF
    Alam, AS
    NEUROLOGY, 2003, 60 (02) : 315 - 321
  • [47] Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial
    Stahl, SM
    Gergel, I
    Li, DY
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (11) : 1322 - 1327
  • [48] Famotidine in the treatment of functional dyspepsia: a randomized double-blind, placebo-controlled trial
    Amini, Mohsen
    Chehreh, Mohammad Ebrahim Ghamar
    Khedmat, Hossein
    Valizadegan, Ghasem
    Babaei, Marzieh
    Darvishi, Ahmad
    Taheri, Saeed
    JOURNAL OF THE EGYPTIAN PUBLIC HEALTH ASSOCIATION, 2012, 87 (1-2): : 29 - 33
  • [49] A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression
    Wagner, KD
    Jonas, J
    Findling, RL
    Ventura, D
    Saikali, K
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (03): : 280 - 288
  • [50] Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Trial
    Panahi, Yunes
    Rahimnia, Ali-Reza
    Sharafi, Mojtaba
    Alishiri, Gholamhossein
    Saburi, Amin
    Sahebkar, Amirhossein
    PHYTOTHERAPY RESEARCH, 2014, 28 (11) : 1625 - 1631